Moloney Securities Asset Management, LLC Jounce Therapeutics, Inc. Transaction History

Moloney Securities Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.9 - $1.85 $214,650 - $441,225	-238,500 Reduced 49.44%	243,950 $451,000
Q4 2022 Jan 30, 2023	BUY	$0.64 - $1.99 $227,276 - $706,686	355,119 Added 278.89%	482,450 $535,000
Q3 2022 Oct 31, 2022	SELL	$2.73 - $4.92 $142,506 - $256,824	-52,200 Reduced 29.08%	127,331 $298,000
Q2 2022 Aug 03, 2022	SELL	$2.8 - $7.67 $205,240 - $562,211	-73,300 Reduced 28.99%	179,531 $544,000
Q1 2022 May 10, 2022	SELL	$6.01 - $8.54 $380,697 - $540,957	-63,344 Reduced 20.03%	252,831 $1.72 Million
Q4 2021 Jan 28, 2022	BUY	$7.11 - $9.64 $241,206 - $327,037	33,925 Added 12.02%	316,175 $2.64 Million
Q3 2021 Oct 27, 2021	BUY	$5.04 - $8.73 $1.34 Million - $2.32 Million	265,650 Added 1600.3%	282,250 $2.1 Million
Q2 2021 Jul 26, 2021	SELL	$6.58 - $10.66 $19,740 - $31,980	-3,000 Reduced 15.31%	16,600 $113,000
Q1 2021 Apr 28, 2021	BUY	$6.73 - $13.87 $131,908 - $271,852	19,600 New	19,600 $201,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Moloney Securities Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Moloney Securities Asset Management, LLC with notifications on news.